Informational only — Not medical advice. Always consult a licensed healthcare provider.

Community data Updated 2 months ago

Indications

Lamo is an antiepileptic drug (AED) indicated for:Epilepsy- adjunctive therapy in patients aged 2 years and older: Partial-onset seizures Primary generalized tonic-clonic seizures Generalized seizures of Lennox-Gastaut syndrome Epilepsy- monotherapy in patients aged 16 years and older.Bipolar disorder- patients aged 18 years and older.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Lamotrigine's exact mechanism of action has not been fully worked out, since it appears to act through several cellular pathways that together account for its usefulness across a range of conditions. Although chemically unrelated to phenytoin and carbamazepine, it produces similar effects: it inhibits voltage-sensitive sodium channels and stabilizes neuronal membranes, which in turn modulates the release of excitatory neurotransmitters from presynaptic nerve endings. Lamotrigine most likely works by binding selectively to sodium channels in their inactive state, blocking sodium currents and suppressing release of the excitatory amino acid glutamate. This same mechanism, which underlies its anticonvulsant activity, is thought to be responsible for its effect in managing bipolar disorder. Research has also found that lamotrigine binds to sodium channels in a manner similar to local anesthetics, which may explain the clinical benefit it shows in certain neuropathic pain conditions.

Lamotrigine also binds to a number of other receptors. In laboratory binding assays, it shows a weak inhibitory effect on the serotonin 5-HT3 receptor, and it binds weakly, with an IC50 above 100 µM, to adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, the kappa-opioid receptor (KOR), muscarinic acetylcholine receptors, and serotonin 5-HT2 receptors. Weak inhibitory effects have also been observed at sigma opioid receptors. An in vivo study found evidence that lamotrigine inhibits Cav2.3 (R-type) calcium currents, a mechanism that may further contribute to its anticonvulsant effects.

Pregnancy & Breastfeeding

Pregnancy Category C. Lamotrigine passes into human breast milk, and nursing infants may be at risk of serious adverse effects from exposure to the drug. Given this, the mother and her doctor should weigh how important the medicine is to her health against the risks to the baby, and decide together whether to stop breastfeeding or stop taking Lamotrigine.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Table 1, the escalation regimen for lamotrigine in patients older than 12 years with epilepsy, is as follows. In weeks 1 and 2, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 25 mg every day; patients taking valproate take 25 mg every other day; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 50 mg per day. In weeks 3 and 4, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 50 mg per day; patients taking valproate take 25 mg every day; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 100 mg per day in two divided doses. From week 5 onward toward the maintenance dose, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate increase the dose by 50 mg per day every one to two weeks; patients taking valproate increase by 25 to 50 mg per day every one to two weeks; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate increase by 100 mg per day every one to two weeks. The usual maintenance dose for patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate is 225 to 375 mg per day in two divided doses. For patients taking valproate, the usual maintenance dose is 100 to 200 mg per day when valproate is the only other drug involved, or 100 to 400 mg per day in one or two divided doses when other drugs that induce glucuronidation are also being taken. For patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate, the usual maintenance dose is 300 to 500 mg per day in two divided doses. Table 2 sets out the escalation regimen for lamotrigine in patients aged 2 to 12 years with epilepsy. In weeks 1 and 2, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 0.3 mg per kg per day in one or two divided doses; patients taking valproate take 0.15 mg per kg per day in one or two divided doses; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 0.6 mg per kg per day in two divided doses. In weeks 3 and 4, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 0.6 mg per kg per day in two divided doses; patients taking valproate take 0.3 mg per kg per day in one or two divided doses; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 1.2 mg per kg per day in two divided doses. From week 5 onward toward the maintenance dose, the dose should be increased every one to two weeks, calculated as 0.6 mg per kg per day for patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate, as 0.3 mg per kg per day for patients taking valproate, and as 1.2 mg per kg per day for patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate. The usual maintenance dose for patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate is 4.5 to 7.5 mg per kg per day, up to a maximum of 300 mg per day in two divided doses. For patients taking valproate, the usual maintenance dose is 1 to 3 mg per kg per day when valproate is the only other drug involved, or 1 to 5 mg per kg per day up to a maximum of 200 mg per day in one or two divided doses when other such drugs are also being taken. For patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate, the usual maintenance dose is 5 to 15 mg per kg per day, up to a maximum of 400 mg per day in two divided doses. Table 3 is the initial weight based dosing guide for patients aged 2 to 12 years who are taking valproate, covering weeks 1 to 4. In weeks 1 and 2, a child weighing 6.7 kg to 14 kg takes 2 mg every other day; a child weighing 14.1 kg to 27 kg takes 2 mg every day; a child weighing 27.1 kg to 34 kg takes 4 mg every day; a child weighing 34.1 kg to 40 kg takes 5 mg every day. In weeks 3 and 4, a child weighing 6.7 kg to 14 kg takes 2 mg every day; a child weighing 14.1 kg to 27 kg takes 4 mg every day; a child weighing 27.1 kg to 34 kg takes 8 mg every day; a child weighing 34.1 kg to 40 kg takes 10 mg every day. Table 4 gives the escalation regimen for lamotrigine in adults with bipolar disorder. In weeks 1 and 2, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 25 mg daily; patients taking valproate take 25 mg every other day; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 50 mg daily. In weeks 3 and 4, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 50 mg daily; patients taking valproate take 25 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 100 mg daily in divided doses. In week 5, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 100 mg daily; patients taking valproate take 50 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 200 mg daily in divided doses. In week 6, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate take 200 mg daily; patients taking valproate take 100 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate take 300 mg daily in divided doses. In week 7, patients not taking carbamazepine, phenytoin, phenobarbital, primidone or valproate continue on 200 mg daily; patients taking valproate continue on 100 mg daily; patients taking carbamazepine, phenytoin, phenobarbital or primidone and not taking valproate may go up to 400 mg daily in divided doses.

Side Effects & Interactions